Parthenolide inhibits Hsp90α ATPase activity and overcomes acquired BRAF-inhibitor resistance in cutaneous melanoma
{{output}}
Background: Oncogenic mutations in the BRAF gene, particularly the V600E mutation, are present in roughly half of metastatic cutaneous melanoma cases. BRAF inhibitors (BRAFi) have shown significant clinical efficacy; however, the... ...
